Home page Random article About FAQ Contact us Donate
New article Recent changes Chopping block Developers
Documentation Bib2Yaml

The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease


Domain: @T
Commit: 2

Status: head
Author: Ender
Date: 06 July 2021, 8:45 (UTC)

is an article about Alzheimer’s and the amyloid hypothesis, a theory which seeks to explain the underlying cause of Alzheimer’s [Fx8]. It was written in the context of the FDA’s controversial [FxB] decision to approve Aducanumab, a new, experimental drug for the treatment of Alzheimer’s. It was written by Laurie McGinley and published by The Washington Post on July 5th, 2021.

Text [edit]

a string of failures. Years of testing drugs that target amyloid buildup have not yielded significant returns, and may be squeezing out other more promising approaches [Ix4].

Medicare’s finances. Aducanumab is an incredibly expensive treatment, and could undermine an already highly weakened Medicare system.

Reference [edit]

Washington Post. n.d. “The Controversial Approval of an Alzheimer’s Drug Reignites the Battle over the Underlying Cause of the Disease.” https://www.washingtonpost.com/health/2021/07/05/aduhelm-new-alzheimers-drug-amyloid/.